axovant
viralgen
sign
strategic
gene
therapy
development
manufacturing
partnership
partnership
secures
access
cgmp
capacity
resources
viralgen
support
development
commercialization
axovant
aav
gene
therapy
programs
gangliosidosis
partnership
bolsters
company
clinical
commercial
capacity
expands
access
process
development
analytical
development
manufacturing
expertise
new
york
basel
switzerland
globe
newswire
axovant
gene
therapies
ltd
nasdaq
axgt
company
developing
innovative
gene
therapies
neurological
diseases
today
announced
signed
strategic
partnership
viralgen
leading
contract
development
manufacturing
organization
cdmo
leveraging
technology
platforms
askbio
viralgen
able
support
aspects
manufacturing
axovant
aav
programs
including
manufacturing
quality
control
environment
bring
therapies
market
quickly
possible
terms
partnership
axovant
access
manufacturing
resources
axovant
gene
therapy
programs
gangliosidosis
gangliosidosis
also
known
sandhoff
disease
sufficient
capacity
support
ongoing
development
eventual
commercialization
pleased
partner
viralgen
emerging
leader
manufacturing
gene
therapies
enable
production
novel
gene
therapies
believe
hold
potential
stabilize
improve
course
gangliosidoses
two
devastating
pediatric
diseases
approved
treatment
options
said
gavin
corcoran
chief
r
officer
axovant
partnership
viralgen
provides
us
access
expansive
facility
highly
skilled
team
focused
delivering
technology
accelerate
development
therapeutics
approach
crucial
continue
advance
aav
programs
data
ongoing
phase
clinical
study
expected
anticipate
ind
clearance
ind
application
year
javiér
garcia
chief
executive
officer
viralgen
said
thrilled
partner
axovant
look
forward
providing
support
priority
access
platform
advance
aav
gene
therapies
rare
fatal
pediatric
diseases
gangliosidosis
viralgen
flexible
scalable
production
platform
ideal
complement
axovant
development
efforts
clinical
trials
commercialization
advance
potential
cures
patients
axovant
gene
therapies
axovant
gene
therapies
gene
therapy
company
focused
developing
pipeline
innovative
product
candidates
debilitating
neurodegenerative
diseases
current
pipeline
gene
therapy
candidates
targets
gangliosidosis
gangliosidosis
also
known
disease
sandhoff
disease
parkinson
disease
axovant
focused
accelerating
product
candidates
clinical
trials
team
experts
gene
therapy
development
external
partnerships
leading
gene
therapy
organizations
information
visit
viralgen
founded
joint
venture
askbio
columbus
venture
partners
spanish
venture
capital
group
viralgen
aav
cgmp
viralgen
licenses
askbio
cell
line
technology
allows
greater
scale
higher
yields
increased
accuracy
aav
therapeutics
based
miramon
parke
san
sebastián
spain
viralgen
cdmo
contract
development
manufacturing
organization
produces
aav
gene
therapy
treatments
enable
pharmaceutical
biotechnology
companies
accelerate
delivery
novel
treatments
improve
patient
lives
key
benefit
technology
cgmp
production
raav
large
batches
unique
robust
manufacturing
platform
viralgen
clinical
facility
suites
operating
able
supply
customers
commercialization
commercial
supply
provided
new
facility
construction
available
late
production
facilities
support
integrated
fill
finish
quality
control
full
support
client
projects
using
platform
information
visit
statements
press
release
contains
statements
purposes
safe
harbor
provisions
private
securities
litigation
reform
act
federal
securities
laws
use
words
may
might
would
expect
believe
estimate
similar
expressions
intended
identify
statements
example
statements
axovant
makes
regarding
costs
associated
operating
activities
statements
based
estimates
assumptions
axovant
management
although
axovant
believes
reasonable
inherently
uncertain
statements
subject
risks
uncertainties
may
cause
actual
results
differ
materially
axovant
expected
risks
uncertainties
include
among
others
impact
pandemic
operations
initiation
conduct
preclinical
studies
clinical
trials
availability
data
clinical
trials
scaling
manufacturing
expectations
regulatory
submissions
approvals
continued
development
gene
therapy
product
candidates
platforms
axovant
scientific
approach
general
development
progress
availability
commercial
potential
axovant
product
candidates
statements
also
subject
number
material
risks
uncertainties
described
axovant
recent
annual
report
form
q
filed
securities
exchange
commission
august
updated
subsequent
filings
securities
exchange
commission
statement
speaks
date
made
axovant
undertakes
obligation
publicly
update
revise
statement
whether
result
new
information
future
events
otherwise
contacts
media
investors
parag
meswani
axovant
gene
therapies
media
investors
